← All Citius Oncology, INC filings

Citius Oncology, INC S-1 registration statements

Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.

NASDAQ
CTOR
Citius Oncology, INC
S-1/A: Citius Oncology Launches Public Offering to Fund LYMPHIR Commercialization Amidst Severe Financial Strain and Going Concern Warning
Citius Oncology, Inc. is offering up to 5,319,149 shares of common stock and accompanying warrants to raise an estimated $13.65 million to fund the commercialization of its FDA-approved oncology drug LYMPHIR, despite significant financial challenges and a going concern warning.
NASDAQ
CTOR
Citius Oncology, INC
S-1: Citius Oncology Files S-1 for $15 Million Capital Raise to Fund LYMPHIR Commercialization Amidst Going Concern Warning
Citius Oncology, Inc. has filed an S-1 registration statement to raise up to $15 million through a public offering of common stock and warrants, aiming to fund the commercialization of its recently FDA-approved oncology drug LYMPHIR, while facing substantial doubt about its ability to continue as a going concern.